(PharmaNewsWire.Com, August 28, 2017 ) In-vivo imagers, also called as preclinical imaging systems, are imaging systems that look deep into the tissues of living subjects. The benefits of this type of system are that it gives the most complete picture of the biological effects of a treatment or disease progression and the animal is kept alive allowing future analysis on the same subject.
In Asia-Pacific region, factors like growing acceptance of preclinical imaging as a legitimate drug development tool and technological advancements in molecular imaging modalities are helping in the growth of the Industry. However, challenges associated with the application of radioisotopes, such as short half-life of PET radioisotopes restricts the demand for micro-PET systems in developing Asian countries.
Asia Pacific Industry for Preclinical In-vivo Imaging is segmented based on Modality and Reagents. Based on modality, the Asia-Pacific preclinical imaging Industry is divided into seven major segments, namely, optical imaging, nuclear imaging, micro-MRI, micro-CT, micro-ultrasound, photoacoustic, and magnetic particle imaging systems. The preclinical optical imaging systems Industry includes bioluminescence/fluorescence imaging systems, standalone fluorescence imaging systems, optical + X-ray/optical + CT imaging systems. The preclinical nuclear imaging systems Industry comprises micro-PET systems (standalone PET, PET/CT, and PET/MRI), micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI), and tri-modality (PET/SPECT/CT) imaging systems. Bases on the reagents, the Asia-Pacific preclinical imaging Industry is divided into five segments, namely, optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, and CT contrast agents. The optical imaging reagents Industry is further sub-segmented as bioluminescent and fluorescent imaging reagents. Likewise, the nuclear imaging reagents Industry is divided as preclinical PET tracers and SPECT probes.
Geographically, Asia Pacific Industry for Preclinical In-vivo Imaging is segmented into China, Japan, India, South Korea and Australia. Increased government funding for development of pharmaceutical industry and rising R&D activities by big pharma and biotech companies, are attracting the companies to invest in the countries of Asia-Pacific region.
Aspect Imaging, Biospace Lab S.A., Bruker Corporation, LI-COR Biosciences, Mediso Ltd., MILabs B.V., MR Solutions Ltd, PerkinElmer, Inc., TriFoil Imaging, and FUJIFILM VisualSonics, Inc. are the key players operating in the Asia-Pacific preclinical imaging systems Industry.
Key Points from Table of Contents Overview Executive Summary Key Inferences New Developments Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) Asia Pacific Preclinical In-vivo Imaging Industry: Segmentation By Modality o Optical imaging o Nuclear imaging o Micro-MRI o Micro-CT o Micro-ultrasound o Photoacoustic o Magnetic particle imaging systems By Reagent o Optical imaging reagents o Nuclear imaging reagents o MRI contrast agents o Ultrasound contrast agents o CT contrast agents Geographical Analysis China India Japan South Korea Strategic Analysis PESTLE analysis Porters Five analysis Industry Leaders' Analysis Competitive Landscape
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
